Skip to content
Search

Latest Stories

RCN calls for urgent investigation into exploitation of migrant care workers

RCN calls for urgent investigation into exploitation of migrant care workers

Rogue employers are misusing repayment clauses to demand large sums of money from migrant care workers, trapping them in appalling conditions

The Royal College of Nursing (RCN) has called on the UK government to launch an urgent investigation into the exploitation of migrant care workers, following a sharp rise in reported cases.

According to new RCN data, there has been a six-fold increase in the number of overseas care workers being exploited by rogue employers over the past three years.


In 2020/21, the RCN's advice team handled 22 calls from members regarding repayment clauses in their contracts. This figure shot up to 134 in 2023/24, with May 2024 alone seeing 17 calls – the highest in a single month.

The RCN highlighted that repayment clauses are being misused by employers to demand thousands of pounds from migrant care workers, leaving staff unable to leave their jobs and trapped in “appalling conditions” years after they were first hired.

“Rather than recouping hiring costs, the clauses are being used to extort money from low-paid migrants,” it said.

The RCN cited a reported case of one care worker who suffered severe bullying and harassment but was unable to leave the role due to a £10,000 repayment demand, despite no specific figure of repayment figure being included in their original contract.

Another worker, who resigned after being assaulted and racially abused at the workplace, was told they owed over £3,000 for visa costs.

A third case involved a worker whose employment was immediately terminated after testing positive for COVID-19, leaving the member jobless and facing a large repayment fee.

RCN General Secretary & Chief Executive Professor Nicola Ranger said: “Rogue employers appear to be forcing migrants to pay thousands of pounds just to leave jobs and threatening them with deportation.

“Those who come to the UK to care for the vulnerable deserve so much better than this exploitation.”

Ranger stressed that the reported cases represent only "the tip of the iceberg," highlighting that migrant workers are often “intimidated and left fearful of speaking out” with some even having their passports withheld.

Moreover, she pointed out that these workers are also much less likely to be members of trade unions.

“The exploitation being allowed to spread is deeply inhumane and undermines the entire social care sector,” Ranger stated.

The RCN is urging the government to fulfill its election campaign promise of investigating these practices.

Ranger said: “Faced with our evidence, ministers were right to commit to an investigation during the election campaign and this must now happen with urgency. Lives are being destroyed every day and this cannot wait. We need action to protect our migrant care workers and raise standards in the sector.”

The RCN hopes to work in partnership with the government to ensure the voices of victims are heard and to develop policy solutions that eradicate these exploitative practices.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less